Danish researchers analyzed data from over 77,000 adults using anti-obesity medications without diabetes. They found that 52 percent stopped taking the drugs within one year. Eighteen percent quit within three months, 31 percent quit within six months, and 42 percent quit after nine months. Younger adults, men, and residents of low-income areas showed the highest dropout rates.
GLP-1 Drugs Lose Effectiveness When Stopped
Ozempic and Wegovy belong to the GLP-1 receptor agonist class, which mimics hormones to reduce appetite. Patients regain weight quickly if they discontinue treatment. Researchers warn that these medications require long-term use to maintain benefits. Professor Reimar W. Thomsen said, “All appetite control advantages vanish when patients stop the medication.”
Side Effects and Health Conditions Influence Quitting
Patients with chronic health issues or prior use of psychiatric and gastrointestinal medications were more likely to quit. Researchers suggest nausea, vomiting, and other side effects prompted some to stop. Adults under 30 had a 48 percent higher chance of quitting than those aged 45 to 59. Residents of low-income neighborhoods were 14 percent more likely to discontinue than those in wealthier areas.
High Costs Limit Access
In Denmark, patients without type 2 diabetes pay up to €313 per month for Ozempic. The price contrasts sharply with Germany, where it costs around €120. Researchers say high costs may prevent patients from maintaining long-term use, especially in poorer communities.
Public Health Implications and Support Needed
Thomsen emphasized that these drugs reduce risks for heart disease, cancer, and addiction. He called for better support systems to help patients continue treatment. “With over half of adults in Europe overweight or obese, we must identify who benefits most and encourage adherence,” he said. He urged policies to improve patient access and long-term outcomes, enhancing both health and quality of life.
Presentation at Diabetes Conference
The study will appear at the European Association for the Study of Diabetes annual meeting in Vienna. Researchers hope the findings inform public health strategies and clinical approaches for weight management.
